¹⁸F-FDG PET/CT Predicts Response to HER2-directed Neoadjuvant Therapy

Comment

Devan Diwanji et al. Radiol Imaging Cancer. 2021 Sep.

. 2021 Sep;3(5):e219021.

doi: 10.1148/rycan.2021219021.

No abstract available

Comment on

Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V. Connolly RM, et al. J Clin Oncol. 2021 Jul 10;39(20):2247-2256. doi: 10.1200/JCO.21.00280. Epub 2021 May 17. J Clin Oncol. 2021. PMID: 33999652 Free PMC article. Clinical Trial.

1. Connolly RM , Leal JP , Solnes L , et al. . Updated results of TBCRC026: Phase II trial correlating standardized uptake value with pathological complete response to pertuzumab and trastuzumab in breast cancer . J Clin Oncol 2021. ; 39 ( 20 ): 2247 – 2256 .doi: 10.1200/jco.21.00280 - DOI - PMC - PubMed